1776 Wealth’s Regeneron Pharmaceuticals REGN Stock Holding History

1776 Wealth’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-76	Closed	-$47K	–	267
2020 Q2	$47K	Sell	76 -36	-32%	-$20.4K	0.03%	193
2020 Q1	$46K	Buy	112 +40	+56%	+$16.5K	0.02%	228
2019 Q4	$27K	Buy	+72	New	+$24.2K	0.02%	222

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

1776 Wealth's REGN Position: Q3 2020 in Review

1776 Wealth sold out of Regeneron Pharmaceuticals (REGN) in Q3 2020, closing a stake of 76 shares — an estimated $47K sold.

1776 Wealth first reported a position in REGN in Q4 2019 and held it in 3 quarters. The position peaked at $47K in Q2 2020. 907 funds tracked by Wall St. Rank hold REGN as of Q3 2020.

1776 Wealth reported no remaining Regeneron Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
1776 Wealth sold 76 Regeneron Pharmaceuticals shares in Q3 2020, an estimated $47K.
1776 Wealth first reported a position in Regeneron Pharmaceuticals in Q4 2019 and held it in 3 quarters.
1776 Wealth's Regeneron Pharmaceuticals position peaked at $47K in Q2 2020.
907 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2020.

Based on 1776 Wealth's 13F filing for Q3 2020, filed 12 Nov 2020.